Italy's DiaSorin ex-Covid revenue in line with guidance
Diasorin 2023 revenue drops 14%, in line with guidance; shares fall
Italy's DiaSorin sees 60% plunge in COVID-19 revenue next year
DiaSorin Acquires COVID-19 Test Maker Luminex For $37 Per Share
DiaSorin to acquire U.S.-based Luminex for around $1.8 billion